epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
Published 2 months ago • 136 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:35
an update on the epcore nhl-1 trial
-
1:11
epcoritamab combined with gemox in b-nhl: updated results from epcore nhl-2
-
1:18
epcore nhl-1: health-related qol in patients with r/r lbcl treated with subcutaneous epcoritamab
-
1:09
early results from epcore cll-1 trial: subcutaneous epcoritamab in patients with richter’s syndrome
-
1:58
ash highlights: glofitamab in dlbcl & pirtobrutinib and epcoritamab in richter's transformation
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
42:47
(a2.1) - origins of cells - ib biology (hl)
-
4:28
i-doublediff & cora technologies - horiba yumizen h550e & yumizen h500e cbc esr analyzers
-
5:29
hy usmle q #739 – heme/onc
-
1:28
diagnostic criteria for castleman disease & the development of a novel symptom score
-
1:38
phase ii study of epcoritamab in r/r lbcl
-
1:07
primary findings from the epcore cll-1 trial of epcoritamab in cll and rt
-
2:22
epcore cll-1: phase i trial of epcoritamab in r/r cll
-
7:16
changes in the classification of dlbcl
-
9:41
subcutaneous epcoritamab in r/r b-cell non-hodgkin lymphoma
-
3:02
the interplay between t-all cells & tecs and the role of tecs in disease progression
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
1:55
first-line venetoclax plus hma vs intensive chemotherapy in older adults with idh-mutated aml
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
2:09
heart transplantation in attr amyloidosis
-
2:38
immune landscape and responses to immune checkpoint blockade in lymphoma